Alkylating agents: all 3,295 studies that test it
Page 24 of 33. Open to participants first (456), then studies with results posted, then the rest; newest registration first within each.
- Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic LeukaemiaStatus unknownNCT01423747Phase 3
- ALL-SCT BFM International- HSCT in Children and Adolescents With ALLStatus unknownNCT01423500Phase 3
- Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01423032Phase 2/3
- Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid MalignanciesCompletedNCT01421173Phase 1
- Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and RituximabCompletedNCT01416974Phase 1
- A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin LymphomaStatus unknownNCT01412307Phase 1/2
- IPI Biochemotherapy for Chemonaive Patients With Metastatic MelanomaTerminatedNCT01409174Phase 1
- Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLCompletedNCT01400685Phase 1
- Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular StageTerminatedNCT01393769Phase 2
- Olaparib and Temozolomide in Treating Patients With Relapsed GlioblastomaCompletedNCT01390571Phase 1
- The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBCStatus unknownNCT01378533Phase 3
- Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic MelanomaCompletedNCT01376713Phase 2
- Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple MyelomaCompletedNCT01376401Phase 2
- Intensified Rituimab Prephase Before FCR in Untreated B-CLLCompletedNCT01370772Phase 2
- Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedNCT01364064Phase 3
- Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed RhabdomyosarcomaCompletedNCT01355445Phase 2
- TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast CancerCompletedNCT01354522Phase 3
- Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)CompletedNCT01352338Phase 1/2
- Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaTerminatedNCT01352312Phase 1
- Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma PatientsCompletedNCT01346787Phase 2
- Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor RemovalTerminatedNCT01341496Phase 1
- Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)Status unknownNCT01339988Phase 4
- Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic MelanomaCompletedNCT01339663Phase 1
- Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)Status unknownNCT01338675Phase 1/2
- Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast CancerTerminatedNCT01329627Phase 2
- Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell LymphomaStatus unknownNCT01322776Phase 1/2
- Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast CancerStatus unknownNCT01321775Phase 2
- BRIEF Bendamustine and Rituximab In Elderly FollicularTerminatedNCT01313611Phase 2
- Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or MediastinumTerminatedNCT01313429Phase 1
- Early Cardiac Toxicity of Adjuvant CT in Elderly BC.TerminatedNCT01301040Phase 2
- A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.TerminatedNCT01289223Phase 3
- Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) TreatmentTerminatedNCT01288131Phase 3
- A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.CompletedNCT01285817Phase 2
- Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell TransplantationCompletedNCT01283776Phase 2
- Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)CompletedNCT01279694Phase 1/2
- A Trial for Systemic Light-chain (AL) AmyloidosisCompletedNCT01277016Phase 3
- A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple MyelomaCompletedNCT01274403Phase 2
- Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AMLStatus unknownNCT01274195Phase 2
- BG & TMZ Therapy of Glioblastoma MultiformeCompletedNCT01269424Phase 1
- A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of ResponseTerminatedNCT01258634Phase 1
- Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's LymphomaCompletedNCT01251107Phase 3
- Umbilical Cord Blood Transplant for Children With Lymphoid Hematological MalignanciesWithdrawnNCT01247688Not applicable
- Temozolomide in Elderly Patients With KPS < 70CompletedNCT01242566Phase 2
- Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant MesotheliomaCompletedNCT01241682Phase 1
- Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT01238146Phase 1/2
- High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating PolyneuropathyWithdrawnNCT01236456Phase 2
- Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast CancerWithdrawnNCT01229605Phase 2
- Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast CancerWithdrawnNCT01227408Phase 2
- Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT01222221Phase 1
- 6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer PatientsStatus unknownNCT01222052Phase 3
- Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)Status unknownNCT01221103Phase 1/2
- A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant GliomaCompletedNCT01220271Phase 1/2
- Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast CancerWithdrawnNCT01219907Phase 1
- Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the EyeStatus unknownNCT01217398Phase 2
- Dendritic Cell Cancer Vaccine for High-grade GliomaCompletedNCT01213407Phase 2
- Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With CancerTerminatedNCT01212887Phase 1
- A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer PatientsStatus unknownNCT01210768Phase 2
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01208766Phase 3
- Tacrolimus Versus Cyclophosphamide as Treatment for Lupus NephritisCompletedNCT01207297Phase 1
- Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast CancerStatus unknownNCT01196455Phase 2
- Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly DiagnosedCompletedNCT01194791Phase 2
- Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk NeuroblastomaActive, not recruitingNCT01192555Phase 1/2
- Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AMLCompletedNCT01191957Phase 3
- Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)CompletedNCT01186640Phase 2
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 DeficiencyActive, not recruitingNCT01176006Phase 2
- Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesCompletedNCT01175785Phase 2
- Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment StrategyTerminatedNCT01175772Phase 2
- Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular CarcinomaTerminatedNCT01171482Phase 2
- Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)WithdrawnNCT01170052Phase 1/2
- Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01168804Phase 2
- Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon CancerTerminatedNCT01167725Phase 3
- Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to LenalidomideCompletedNCT01166113Phase 1/2
- Bendamustine and Bevacizumab for Advanced CancersCompletedNCT01152203Phase 1
- Study of Chemo-Immunotherapy in Head and Neck Cancer PatientsStatus unknownNCT01149902Phase 1
- Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT01149850Phase 2
- Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder CancerCompletedNCT01149174Phase 3
- Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma PatientsCompletedNCT01149109Phase 3
- Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasTerminatedNCT01143545Phase 1
- Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT01141244Phase 1
- Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)Active, not recruitingNCT01140373Phase 1
- PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & OfatumumabWithdrawnNCT01131247Phase 2
- Metronomic Therapy in Metastatic Breast Cancer.CompletedNCT01131195Phase 3
- Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic AnemiaWithdrawnNCT01129323Not applicable
- Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First LineStatus unknownNCT01127841Phase 2
- Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb InfusionCompletedNCT01127594Phase 1
- Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and OfatumumabTerminatedNCT01125787Phase 2
- Myocet Plus Endoxan for Older Patients With Breast CancerTerminatedNCT01120171Phase 2
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaCompletedNCT01117441Phase 3
- Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma PatientsTerminatedNCT01116128Phase 2
- Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)Status unknownNCT01114048Phase 2
- Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic LeukemiaCompletedNCT01109264Phase 2
- Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant GliomasStatus unknownNCT01107522Phase 1
- Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic MelanomaTerminatedNCT01106235Phase 1
- Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic AnemiaCompletedNCT01105273Phase 1/2
- Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue SarcomaCompletedNCT01102608Phase 2
- Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable GlioblastomaCompletedNCT01102595Phase 2
- Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder CancerStatus unknownNCT01094964Phase 3
- Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma PatientsCompletedNCT01093196Phase 3
- Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01091831Phase 3